If you need more lookups,
subscriptions start at $34 USD/month.
Aleks Davis Location
Indianapolis, IN, US
Aleks Davis Work
2016 -now CEO @
2016 -now Chief Executive Officer @
2022 -now Board Member @
2012 -2016 Global Director @
2010 -2012 Bioethics Development Program @ Eli Lilly and Company
2009 -2012 Patient Privacy Steward @ Eli Lilly and Company
2009 -2012 Biobank and Tailored Therapeutics Program Manager @ Eli Lilly and Company
2000 -2009 Organic and Immunoanalytical Chemist @ Eli Lilly and Company
Aleks Davis Education
PU 2018-2018
Indiana University
Master Of Business Administration (Business)
2013-2014
Indiana University - Purdue University - Indianapolis
(Chemistry)
2000-2001
Georgia Southern University
Bachelor Of Science (Chemistry)
1995-2000
Aleks Davis Skills
Laboratory
Sample Management
Clinical Trials
Immunoassays
CRO
Chemistry
GMP
Antibodies
Data Privacy
Laboratory Analysis
Clinical Research
Assay Development
Biotechnology
IND
DNA
Validation
Pre Analytical Sample Preparation
Translational Research
Drug Discovery
Business Planning
Reagents
Lifesciences
Analytical Chemistry
Biobanking
Program Management
Oncology
Organic Chemistry
Drug Development
GCP
Cross Functional Team Leadership
Clinical Development
Monoclonal Antibodies
Bioethics
Project Implementation
Dishwashing
Regulatory Submissions
Strategic Consulting
Pharmaceutical Industry
DNA extraction
Technology Transfer
GLP
Personalized Medicine
Biomarkers
Peptide Synthesis
FDA
Protein Chemistry
Sop
21 CFR Part 11
Commercialization
Biopharmaceuticals
Aleks Davis Summary
Aleks Davis, based in Indianapolis, IN, US, is currently a CEO at B2S Life Sciences. Aleks Davis brings experience from previous roles at B2s Life Sciences, Franklin Chamber of Commerce, Icon PLC and Eli Lilly and Company. Aleks Davis holds a 2018 - 2018 PU. With a robust skill set that includes Laboratory, Sample Management, Clinical Trials, Immunoassays, CRO and more. Aleks Davis has 3 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Aleks Davis?
Find contact details for 700 million professionals.